Miyai Takayuki, Imai Shungo, Kashiwagi Hitoshi, Sato Yuki, Kadomura Shota, Yoshida Kenji, Yoshimura Eri, Teraya Toshiaki, Tsujimoto Takashi, Kawamoto Yukari, Itoh Tatsuya, Ueno Hidefumi, Goto Yoshikazu, Takekuma Yoh, Sugawara Mitsuru
Graduate School of Life Science, Hokkaido University, Sapporo 060-0810, Japan.
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.
Antibiotics (Basel). 2020 Dec 18;9(12):920. doi: 10.3390/antibiotics9120920.
We previously constructed a risk prediction model of vancomycin (VCM)-associated nephrotoxicity for use when performing initial therapeutic drug monitoring (TDM), using decision tree analysis. However, we could not build a model to be used at the time of initial administration due to insufficient sample size. Therefore, we performed a multicenter study at four hospitals in Japan. We investigated patients who received VCM intravenously at a standard dose from the first day until the initial TDM from November 2011 to March 2019. Acute kidney injury (AKI) was defined according to the criteria established by the "Kidney disease: Improving global outcomes" group. We extracted potential risk factors that could be evaluated on the day of initial administration and constructed a flowchart using a chi-squared automatic interaction detection algorithm. Among 843 patients, 115 (13.6%) developed AKI. The flowchart comprised three splitting variables (concomitant drugs (vasopressor drugs and tazobactam/piperacillin) and body mass index ≥ 30) and four subgroups. The incidence rates of AKI ranged from 9.34 to 36.8%, and they were classified as low-, intermediate-, and high-risk groups. The accuracy of flowchart was judged appropriate (86.4%). We successfully constructed a simple flowchart predicting VCM-induced AKI to be used when starting VCM administration.
我们之前使用决策树分析构建了一个万古霉素(VCM)相关肾毒性的风险预测模型,用于初始治疗药物监测(TDM)。然而,由于样本量不足,我们未能构建出可在初始给药时使用的模型。因此,我们在日本的四家医院开展了一项多中心研究。我们调查了2011年11月至2019年3月期间从第一天开始接受标准剂量静脉注射VCM直至进行初始TDM的患者。急性肾损伤(AKI)根据“改善全球肾脏病预后组织”制定的标准进行定义。我们提取了在初始给药当天可评估的潜在风险因素,并使用卡方自动交互检测算法构建了一个流程图。在843例患者中,115例(13.6%)发生了AKI。该流程图包含三个分裂变量(合并用药(血管加压药和他唑巴坦/哌拉西林)以及体重指数≥30)和四个亚组。AKI的发生率在9.34%至36.8%之间,被分为低、中、高风险组。该流程图的准确性被判定为合适(86.4%)。我们成功构建了一个简单的流程图,用于预测开始使用VCM时VCM诱发的AKI。